Minimum inhibitory and bactericidal concentrations of four antibiotics and their combinations were determined for 38 strains of enterococci by a microtitration tube dilution technique. The drugs were ampicillin, vancomycin, gentamicin, and streptomycin; the combinations were ampicillin-gentamicin, ampicillin-streptomycin, vancomycin-gentamicin, and vancomycin-streptomycin. At achievable serum concentrations, ampicillin alone killed 60% of strains, whereas combination with streptomycin increased this to 90% and with gentamicin to 100%. Vancomycin alone showed striking inhibitory activity, but very poor bactericidal activity at achievable concentrations. Combination with one of the aminoglycosides increased the bactericidal activity substantially. When combined with ampicillin, gentamicin was both more active and showed synergistic bactericidal activity significantly more often (P < 0.01) than streptomycin.
Despite the advent of new antibiotics, endocarditis due to the group D Streptococcus (enterococcus) has remained more difficult to treat successfully than endocarditis due to other streptococci (9) . This difficulty is likely because of the organism's relative resistance to antibiotics. Early studies demonstrating synergistic activity between penicillin and streptomycin (7) led to the establishment of this combination as standard therapy for enterococcal endocarditis. Mortality rates for this disease have remained relatively high, however (8) , and a significant number of strains do not respond to this combination (15) . Other regimens, including penicillin plus kanamycin (6) , ampicillin alone (1) , and ampicillin plus streptomycin (12) have been proposed. More recently, very low concentrations of gentamicin have been reported to act synergistically with penicillin (13) . Because previous experiments from this laboratory (14) have suggested that both ampicillin alone and ampicillin plus streptomycin were more active than penicillin plus streptomycin, we compared the in vitro effectiveness of the ampicillin-gentamicin combination with that of ampicillin-streptomycin to see if this activity of ampicillin could be enhanced by use of another aminoglycoside.
Alternate therapy for enterococcal endocarditis in patients who cannot tolerate penicillin or its derivatives remains an open question. Vancomycin alone has been suggested (4, 12) , but the wide gap between concentrations of vancomycin which inhibit and those which kill the enterococcus (3) has encouraged search for ways to increase the effectiveness of this drug. Streptomycin has been found to act synergistically with vancomycin in vitro (11) , and at least one patient has been treated successfully with this combination (17) . To confirm and extend these studies to the use of another aminoglycoside, we compared the activity of vancomycin plus streptomycin with that of vancomycin plus gentamicin.
MATERIALS AND METHODS
Thirty-eight strains of enterococci were studied. Of these, 31 were isolated in the clinical laboratory: 17 from urine, 10 from local infections, 3 from sputum, 2 from cerebrospinal fluid, and 1 from ascitic fluid. The remainder consisted of four strains from the American Type Culture Collection and the GK strain, whose antibiotic sensitivities have been previously described (14) . Identification as an enterococcus was established by Gram-stain morphology, negative catalase reaction, growth in 6.5% salt medium at pH 9.4, and growth in 0.05% sodium azide with acid production (SF medium, Difco).
Antibiotics were prepared in frozen stock solutions at the following concentrations (jLg/ml): sodium ampicillin, 800 and 100; vancomycin hydrochloride, 800 and 100; gentamicin sulfate, 1,600 and 800; and streptomycin sulfate, 12,800 and 6,400.
For single antibiotic sensitivity determinations, the test was performed by using a microtitration technique previously outlined (5) 
RESULTS
Antibiotic sensitivities of the enterococci to the four individual drugs are shown in Fig. 1-4 . At achievable blood levels few isolates were inhibited or killed by gentamicin (Fig. 1) or streptomycin (Fig. 2) . Ampicillin (Fig. 3) showed inhibitory activity at achievable concentrations, but 200 ,ug/ml was required for bactericidal activity against all 38 strains. Vancomycin (Fig. 4) was extremely active, inhibiting 96% of strains at 3.125 ug/ml. However, concentrations required for bactericidal activity were 4 to 500 times greater.
Results of antibiotic combination studies are shown in Fig. 5-8 . The effect of adding gentamicin or streptomycin to vancomycin was not striking when only the inhibitory concentrations were examined ( Fig. 5A and 6A ), but both streptomycin and gentamicin dramatically enhanced bactericidal activity ( Fig. 5B and 6B) . Streptomycin, however, required concentrations very difficult to achieve clinically (100 Ag/ml with 12.5 ,ug of vancomycin per ml) to kill 90% of strains, whereas achievable concentrations of gentamicin (12.5 Ag/ml) and vancomycin (6.25 ug/ml) showed sufficient activity in combination to kill all 38 strains.
Tests of the combinations with ampicillin showed similar results. Although the difference between gentamicin (Fig. 7A and 7B ) and streptomycin ( Fig. 8A and 8B ) was less striking than with the vancomycin combinations, gentamicin plus ampicillin was the more active pair. The frequency of occurrence of synergistic bactericidal activity for the four drug combinations is shown in Table 1 . When combined with ampicillin, gentamicin showed synergistic activity significantly more often than did streptomycin (P < 0.01). The same trend was seen with vancomycin. When synergism was demonstrated, it occurred at or below achievable levels in every case. No evidence of antagonism was seen.
In testing penicillin-streptomycin combinations, Standiford et al. (15) observed that synergism was not likely to occur when the MIC for streptomycin of a given enterococcus was greater than 250 ,g/ml.
Our studies suggest that no such relationship exists between the activity of streptomycin and likelihood of synergistic activity between streptomycin and ampicillin. Table 2 shows that whatever dividing line was chosen for the MIC of streptomycin, the likelihood of synergistic bactericidal activity occurring was essentially the same at higher or lower concentrations.
The gentamicin MICs or MBCs also had no antimicrobial activity against a variety of strains of enterococci by using combinations of either ampicillin or vancomycin with gentamicin or streptomycin. In each case the combination with gentamicin was more active at a lower concentration and was more likely to show synergistic bactericidal activity than was streptomycin. DISCUSSION Concem over achieving bactericidal rather than bacteriostatic activity in patients with endocarditis is based on experience that bacteriostatic antibiotics often fail to cure the disease (2) . The ready synergism of vancomycin and gentamicin, despite the obvious toxicity of both drugs, would seem to make this combination very effective alternative therapy to penicillin or ampicillin in combination and should allow the achievement of serum bactericidal activity in the patient with serious penicillin allergy.
These data suggest the use of gentamicin as the aminoglycoside of choice in the combination antibiotic therapy of enterococcal infection based on in vitro evidence of its greater activity over streptomycin. Unfortunately, gentamicin is also a more toxic drug, and little clinical data is available at this time to support its use in endocarditis. However, in the patient not responding well to conventional penicillin-streptomycin therapy, and in the situation where laboratory facilities for determination of serum bactericidal activity are not available, the use of ampicillin plus gentamicin or, if necessary, vancomycin plus gentamicin should be considered. Recent experiments treating enterococcal pyelonephritis in the rat (Harwick, Kalmanson, and Guze, J. Infect. Dis., in press) have confirmed the in vitro data regarding the antimicrobial activity of the vancomycin-gentamicin combination.
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